Legacy Wealth Asset Management’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-813
Closed -$266K – 365
2024
Q4
$266K Sell
813
-23
-3% -$7.24K 0.07% 320
2024
Q3
$251K Buy
836
+13
+2% +$3.98K 0.07% 325
2024
Q2
$271K Buy
823
+22
+3% +$7.78K 0.08% 306
2024
Q1
$317K Buy
801
+2
+0.3% +$740 0.09% 292
2023
Q4
$281K Buy
799
+2
+0.3% +$708 0.09% 299
2023
Q3
$299K Sell
797
-18
-2% -$6.96K 0.11% 279
2023
Q2
$312K Buy
815
+10
+1% +$3.57K 0.11% 284
2023
Q1
$279K Buy
+805
New +$235K 0.1% 296
2022
Q4
– Sell
-877
Closed -$216K – 348
2022
Q3
$216K Buy
877
+9
+1% +$2.74K 0.09% 299
2022
Q2
$262K Sell
868
-1
-0.1% -$325 0.11% 250
2022
Q1
$357K Buy
869
+6
+0.7% +$2.35K 0.13% 229
2021
Q4
$405K Sell
863
-24
-3% -$10.3K 0.14% 225
2021
Q3
$377K Sell
887
-25
-3% -$10.5K 0.17% 214
2021
Q2
$327K Sell
912
-42
-4% -$13.9K 0.15% 237
2021
Q1
$269K Sell
954
-6
-0.6% -$1.72K 0.12% 253
2020
Q4
$272K Buy
+960
New +$269K 0.14% 244

Other funds holding WST

Legacy Wealth Asset Management's WST Position: Q1 2025 in Review

Legacy Wealth Asset Management sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 813 shares — an estimated $266K sold.

Legacy Wealth Asset Management first reported a position in WST in Q4 2020 and held it in 16 quarters. The position peaked at $405K in Q4 2021. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Legacy Wealth Asset Management reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Legacy Wealth Asset Management sold 813 West Pharmaceutical shares in Q1 2025, an estimated $266K.
  • Legacy Wealth Asset Management first reported a position in West Pharmaceutical in Q4 2020 and held it in 16 quarters.
  • Legacy Wealth Asset Management's West Pharmaceutical position peaked at $405K in Q4 2021.
  • 715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Legacy Wealth Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.